Driscoll Michael Joseph 4

What Happened

• Michael Joseph Driscoll, a director of Organogenesis Holdings, was granted 48,828 restricted stock units (RSUs) on 2026-02-18. The grant is recorded at $0 acquisition price (i.e., no cash paid) and thus has no immediate cash value in the filing.
• These RSUs represent the contingent right to receive one share of Organogenesis Class A common stock per RSU upon vesting; the award vests in full on February 15, 2027.

Key Details

• Transaction date: 2026-02-18; Filing (Form 4) accession: 0002064832-26-000056, filed 2026-02-20.
• Transaction type/code: Award/Grant (A); price reported: $0.00; total shown value: $0.
• Shares granted: 48,828 RSUs (each converts to one Class A share upon vesting).
• Shares owned after transaction: Not disclosed in this filing.
• Notable footnote: RSUs issued under the Organogenesis 2018 Equity Incentive Plan; vest in full on 2/15/2027.
• Timeliness: Filing dated two days after the grant date; appears to be within the common 2-business-day Form 4 reporting window.

Context

• RSU grants are compensation awards, not open-market purchases or sales; they do not represent immediately tradable shares until they vest and are settled. Such awards are routine for directors and employees and are not direct indicators of immediate buying or selling sentiment.